2010年-世界发展银行全球_Assessment_of_Governance_and_Corruption_in_the_Pharmaceutical_Sector___Lessons_Learned_from_Low_and_Middle_Income_Countries_42页_2mb

Summary of Assessment of Governance and Corruption in the Pharmaceutical Sector – Lessons learned from Low and Middle Income Countries

Core Content

This document presents an assessment of governance and corruption in the pharmaceutical sector across eight low and middle-income countries (LICs and LMICs). It highlights the challenges in ensuring access to affordable, quality medicines and the role of governance in shaping the effectiveness of health systems.

The pharmaceutical sector is a critical component of health service delivery, particularly for achieving health-related Millennium Development Goals (MDGs). Access to essential medicines and vaccines is vital for improving health outcomes, yet many countries face issues such as high drug prices, stock-outs, and irrational drug use. These problems are often linked to poor governance, weak institutional capacity, and corruption.

The study emphasizes the importance of good governance in maximizing public health returns and minimizing risks to patients from ineffective or contaminated drugs. It argues that addressing governance issues in the pharmaceutical sector is not straightforward due to political and institutional resistance, especially from those benefiting from the current status quo.

Main Viewpoints

• Pharmaceuticals are a key input for health outcomes and their availability and affordability are crucial for effective healthcare delivery.
• Corruption is a significant risk in the pharmaceutical sector, particularly in areas such as licensing, formulary inclusion, procurement, and drug distribution.
• Poor governance and institutional capacity are major underlying factors in the observed sectoral dysfunction, including inadequate regulation, inefficient supply chains, and lack of transparency.
• The private sector dominates drug supply in most countries, often at inflated prices, and is not adequately regulated or monitored.
• Public sector governance systems are frequently under-resourced, leading to issues like poor data management, lack of enforcement, and weak oversight.
• Corruption is not the only cause of sectoral problems, and the assessment framework aims to identify patterns that may indicate governance or management issues, rather than focusing solely on corruption itself.

Key Information

Assessment Methodology

• A neutral, structured checklist was used to assess the pharmaceutical sector, covering key areas such as market dynamics, policy and regulation, public and private drug expenditure, service delivery, logistics, and rational drug use.
• The tool is flexible and customizable, allowing for country-specific adaptations based on the needs and political realities of each nation.
• The assessment avoids a narrow focus on corruption, instead aiming to identify systemic governance and management issues that may contribute to sectoral dysfunction.

Country Selection and Findings

• Countries were selected based on demand and political viability, with participation from four World Bank regions: Africa, Latin America, East Asia, and the Middle East.
• Benin, Ghana, Indonesia, Liberia, Peru, Timor Leste, West Bank/Gaza, and Yemen were included in the study.
• The assessment framework was applied with adjustments to fit local contexts, and follow-up was documented in most cases, showing the relevance and impact of findings in national policy discussions.

Observations

• Private sector dominance in drug supply is widespread, with high out-of-pocket expenditures in most countries.
• High drug prices in both public and private sectors contribute to the growth of the informal market.
• Weak regulatory capacity is a common issue, with limited staffing, funding, and laboratory facilities.
• Lack of quality control and poor enforcement lead to the presence of sub-standard and counterfeit drugs in the market.
• Public sector supply chains are often inefficient, resulting in stock-outs and overstocking, especially in remote areas.
• Informal drug markets are particularly prevalent in countries with weak governance structures, such as Yemen and Benin.

Recommendations and Implications

• Improving governance and management systems is essential for enhancing the efficiency and equity of pharmaceutical supply.
• Transparency and accountability mechanisms, such as electronic procurement platforms and inventory management systems, can help reduce the risk of corruption.
• Public-private partnerships and framework contracts with private providers may offer viable alternatives to improve drug availability and reduce the burden on the public sector.
• Strengthening regulatory frameworks and institutional capacity is necessary to ensure the quality and safety of medicines.
• Community-based health insurance and decentralized financing mechanisms can support more sustainable and responsive pharmaceutical systems.

Conclusion

The study demonstrates that addressing pharmaceutical governance and corruption can be effectively done through sector-wide assessments that focus on systemic issues rather than isolated acts of corruption. By using a neutral diagnostic approach, it is possible to identify patterns of dysfunction and guide reforms in a way that is politically acceptable and actionable. The findings highlight the need for context-sensitive strategies and capacity building in regulatory and supply chain functions to improve health outcomes and ensure equitable access to medicines.